Etanercept Biosimilar Launch Saves Aussie Govt $6M: Pricing Policy Update
TL/DR -
The United States has approved two biosimilars for etanercept (Enbrel) but patent litigation has delayed their market launch until 2029. Sales of Enbrel reached $4 billion in 2022, and the drug is being targeted for Medicare price negotiation under the Inflation Reduction Act. Meanwhile, Australia has been using the first etanercept…